PE20040929A1 - Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas - Google Patents

Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas

Info

Publication number
PE20040929A1
PE20040929A1 PE2004000008A PE2004000008A PE20040929A1 PE 20040929 A1 PE20040929 A1 PE 20040929A1 PE 2004000008 A PE2004000008 A PE 2004000008A PE 2004000008 A PE2004000008 A PE 2004000008A PE 20040929 A1 PE20040929 A1 PE 20040929A1
Authority
PE
Peru
Prior art keywords
methyl
pyrrol
cycloalkyl
carboxyl
phenyl
Prior art date
Application number
PE2004000008A
Other languages
English (en)
Inventor
Werner Englberger
Hagen-Heinrich Hennies
Corinna Sundermann
Babette-Yvonne Koegel
Beatrix Merla
Utz-Peter Jagusch
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20040929A1 publication Critical patent/PE20040929A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A AMIDAS DE ACIDO 5-AMINOMETIL-1H-PIRROL-2-CARBOXILICO SUBSTITUIDAS DE FORMULA I DONDE R1 ES H, ALQUILO, CICLOALQUILO CON HETEROATOMO COMO MIEMBRO DEL ANILLO, ARILO, HETEROARILO, ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO CON HETEROATOMO COMO MIEMBRO DEL ANILLO, ARILO, ENTRE OTROS; R1 Y R2 JUNTO CON EL N AL QUE ESTAN UNIDOS FORMAN UN CICLOALQUILO SATURADO O INSATURADO; R3 ES ARILO, HETEROARILO, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, CICLOALQUILO ENTRE OTROS; R4 Y R5 JUNTO A N FORMAN UN RESTO CICLOALQUILO SATURADO O INSATURADO, ENTRE OTROS; R6 ES ALQUILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS CICLOHEXILAMIDA DE ACIDO 5-[DIMETILAMINO-(4-FLUORO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-CARBOXILICO, BUTILAMIDA DE ACIDO 5-[DIMETILAMINO(4-FLUORO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-CARBOXILICO, {5-[DIMETILAMINO-(4-FLUORO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-I}-PIRROLIDIN-1-IL-METANONA, CICLOHEXILAMIDA DE ACIDO 5-[DIMETILAMINO-(4-BROMO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-CARBOXILICO, ENTRE OTROS. SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES. LOS COMPUESTOS MENCIONADOS TIENEN ALTA AFINIDAD POR EL RECEPTOR OPIOIDE (ORL-1) Y SON UTILES PARA EL TRATAMIENTO DE DOLORES CRONICOS, AGUDOS, NEUROPATICOS
PE2004000008A 2002-12-20 2004-01-05 Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas PE20040929A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10261131A DE10261131A1 (de) 2002-12-20 2002-12-20 Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide

Publications (1)

Publication Number Publication Date
PE20040929A1 true PE20040929A1 (es) 2005-01-07

Family

ID=32404308

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000008A PE20040929A1 (es) 2002-12-20 2004-01-05 Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas

Country Status (9)

Country Link
US (1) US7229991B2 (es)
EP (1) EP1581490B1 (es)
AR (1) AR042521A1 (es)
AT (1) ATE496887T1 (es)
AU (1) AU2003294900A1 (es)
DE (2) DE10261131A1 (es)
ES (1) ES2356446T3 (es)
PE (1) PE20040929A1 (es)
WO (1) WO2004058707A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041274A1 (en) * 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
EA016558B1 (ru) 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
EA200600071A1 (ru) * 2003-06-20 2006-08-25 Арена Фармасьютикалз, Инк. Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
DE102004024772A1 (de) 2004-05-17 2005-12-22 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
SG158168A1 (en) * 2004-12-23 2010-01-29 Arena Pharm Inc 5ht2c receptor modulator compositions and methods of use
EP2192838A4 (en) * 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
WO2009111004A1 (en) * 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
WO2012030939A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
MX2013002421A (es) 2010-09-01 2013-05-17 Arena Pharm Inc Sales no hidroscopicas de agonistas de 5-ht2c.
KR101913442B1 (ko) 2010-09-01 2018-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551571A (en) * 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
AU2001271631A1 (en) * 2000-06-30 2002-01-14 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
ATE369354T1 (de) * 2000-12-20 2007-08-15 Ortho Mcneil Pharm Inc Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems
US6849730B2 (en) * 2001-09-25 2005-02-01 North Carolina State University Methods of making porphyrins and related compounds with Lewis acids

Also Published As

Publication number Publication date
ES2356446T3 (es) 2011-04-08
ATE496887T1 (de) 2011-02-15
US20050288342A1 (en) 2005-12-29
DE50313444D1 (en) 2011-03-10
US7229991B2 (en) 2007-06-12
EP1581490B1 (de) 2011-01-26
DE10261131A1 (de) 2004-07-01
AU2003294900A1 (en) 2004-07-22
AR042521A1 (es) 2005-06-22
EP1581490A1 (de) 2005-10-05
WO2004058707A1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
PE20040929A1 (es) Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
RU2400483C2 (ru) Пуриновые производные в качестве агонистов рецептора a2a
AR077818A1 (es) Composiciones pesticidas
PE20071080A1 (es) Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20091444A1 (es) Derivados de isoxazolo-pirazina
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
EA200400387A1 (ru) Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний
PE20070194A1 (es) Compuestos de pirazolina 4-sustituidos como moduladores de cb1
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR068054A1 (es) Compuestos de pirrolopirimidina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
PE20100144A1 (es) Compuestos quimicos 293
JP2018502148A5 (es)
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal